Enhanced Active Targeting via Cooperative Binding of Ligands on Liposomes to Target Receptors

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Sugiyama, Tomoki ^a   Asai, Tomohiro ^a   Nedachi, Yuki Murase ^a   Katanasaka, Yasufumi ^a   Shimizu, Kosuke ^a   Maeda, Noriyuki ^b   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Nippon Fine Chemical Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLPROLYLARGINYLPROLYLGLYCINE; ARGINYLGLYCYLASPARTIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; GLYCYLARGINYLGLYCYLASPARTYLSERINE; LIPOSOME; MACROGOL; PEPTIDE; PROLYLARGINYLPROLINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VITRONECTIN RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER CELL CULTURE; CELL SURFACE; CELLULAR DISTRIBUTION; CHEMICAL BINDING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COOPERATIVE BINDING; LIGAND BINDING; LIPOSOMAL DELIVERY; PROTEIN IMMOBILIZATION; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SURFACE PLASMON RESONANCE; SURFACE PROPERTY; TARGET CELL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIGENS, CD13; CELLS, CULTURED; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; LIGANDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

MUS;

EID: 84879545989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067550     Document Type: Article

References (24)

1. Matsumura Y, Maeda H, (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
2. Maeda H, Matsumura Y, (2011) EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. http://www.ncbi.nlm.nih.gov/pubmed/20457195Adv Drug Deliv Rev 63: 129-130.
3. Hatakeyama H, Akita H, Harashima H, (2011) PEG-direnmaA multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63: 152-160.
4. Ichikawa K, Hikita T, Maeda N, Takeuchi Y, Namba Y, et al. (2004) PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy. Biol Pharm Bull 27: 443-444.
5. Lammers T, Kiessling F, Hennink WE, Storm G, (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161: 175-187.
6. Fay F, Scott CJ, (2011) Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 3: 381-394.
7. Nishikawa K, Asai T, Shigematsu H, Shimizu K, Kato H, et al. (2012) Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. J Control Release 160 274-280.
8. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, et al. (1997) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118: 153-160.
9. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, et al. (2005) Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 94: 1782-1793.
10. Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, et al. (2002) Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21: 2662-2669.
11. Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, et al. (2002) Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett 520: 167-170.
12. Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, et al. (2011) Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull 34: 602-608.
13. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W, (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7: 1249-1253.
14. Arap W, Pasqualini R, Ruoslahti E, (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
15. Ruoslahti E, (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12: 697-715.
16. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, et al. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727.
17. Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, et al. (2004) Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100: 41-52.
18. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, et al. (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63: 7400-7409.
19. Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, et al. (2010) A novel DDS strategy, "dual-targeting". and its application for antineovascular therapy. Cancer Lett 287: 165-171.
20. Tsuruo T, Yamori T, Naganuma K, Hori K, Kawabata H, et al. (1984) Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. Gann 75: 193-198.
21. O'Reilly MS, Holmgren L, Chen C, Folkman J, (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692.
22. Shimizu K, Asai T, Fuse C, Sadzuka Y, Sonobe T, et al. (2005) Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int J Pharm 296: 133-141.
23. Yonezawa S, Asai T, Oku N, (2007) Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. J Control Release 118: 303-309.
24. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.